BioLineRx Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $28.9M | $4.8M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| Operating Income | $-10.3M | $-20.4M | $-49.7M | $-29.2M | $-24.8M |
| Operating Margin | -871.8% | -70.5% | -1,035.3% | — | — |
| Interest Expense | $1.3M | $9.1M | $2.1M | $1.8M | $984.0K |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-2.0M | $-9.2M | $-60.6M | $-25.0M | $-27.1M |
| Net Margin | -171.7% | -31.9% | -1,262.8% | — | — |
| EPS (Basic) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 |
| EPS (Diluted) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 |
| Shares Outstanding (Basic) | 2.23B | — | 1.09B | 923.0M | 715.2M |
| Shares Outstanding (Diluted) | 2.23B | — | 1.09B | 923.0M | 715.2M |
| Dividends Per Share | — | — | — | — | — |